File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong

TitleIn-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong
Authors
KeywordsAntiretroviral therapy
Drug resistance
Genotype
Highly active
HIV-1
Missense
Mutation
Viral
Issue Date2012
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2012, v. 18 n. 1, p. 20-24 How to Cite?
AbstractObjective To determine the frequency of highly active antiretroviral therapy resistance mutations in the viral pol gene of human immunodeficiency virus-1 (HIV-1) genotypes that circulate in Hong Kong, by means of an in-house HIV-1 genotyping system. Design Retrospective study. Setting Two HIV clinics in Hong Kong. Patients A modified in-house genotyping resistance test was used to sequence the partial pol gene in 1165 plasma samples from 965 patients. The performance of our test was cross-compared with the US Food and Drug Administration-approved ViroSeq HIV-1 genotyping system. The results of genotyping were submitted to the Stanford HIV-1 drug resistance database for analysis. Results The cost-effective in-house genotypic resistance test (US$40) demonstrated comparable performance to the US Food and Drug Administration-approved ViroSeq system. The detection limit of this in-house genotypic resistance test could reach 400 copies/mL for both HIV-1 subtype B and CRF01_AE, which were the predominant genotypes in Hong Kong. Drug resistance mutations were detected only in post-treatment samples from treatment-failure patients. However, there was no significant difference in the frequency of drug resistance mutations between subtype B and CRF01_AE. Conclusion Our cost-effective in-house genotypic resistance test detected no significant difference in drug resistance-related mutations frequencies between HIV-1 subtype B and CRF01_AE in Hong Kong. A drug resistance-related mutations database for different HIV-1 genotypes should be established in Hong Kong to augment guidance for HIV treatment.
Persistent Identifierhttp://hdl.handle.net/10722/157679
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChen, JHKen_US
dc.contributor.authorWong, KHen_US
dc.contributor.authorLi, PCKen_US
dc.contributor.authorChan, KKCen_US
dc.contributor.authorLee, MPen_US
dc.contributor.authorTo, SWCen_US
dc.contributor.authorYam, WCen_US
dc.date.accessioned2012-08-08T08:52:12Z-
dc.date.available2012-08-08T08:52:12Z-
dc.date.issued2012en_US
dc.identifier.citationHong Kong Medical Journal, 2012, v. 18 n. 1, p. 20-24en_US
dc.identifier.issn1024-2708en_US
dc.identifier.urihttp://hdl.handle.net/10722/157679-
dc.description.abstractObjective To determine the frequency of highly active antiretroviral therapy resistance mutations in the viral pol gene of human immunodeficiency virus-1 (HIV-1) genotypes that circulate in Hong Kong, by means of an in-house HIV-1 genotyping system. Design Retrospective study. Setting Two HIV clinics in Hong Kong. Patients A modified in-house genotyping resistance test was used to sequence the partial pol gene in 1165 plasma samples from 965 patients. The performance of our test was cross-compared with the US Food and Drug Administration-approved ViroSeq HIV-1 genotyping system. The results of genotyping were submitted to the Stanford HIV-1 drug resistance database for analysis. Results The cost-effective in-house genotypic resistance test (US$40) demonstrated comparable performance to the US Food and Drug Administration-approved ViroSeq system. The detection limit of this in-house genotypic resistance test could reach 400 copies/mL for both HIV-1 subtype B and CRF01_AE, which were the predominant genotypes in Hong Kong. Drug resistance mutations were detected only in post-treatment samples from treatment-failure patients. However, there was no significant difference in the frequency of drug resistance mutations between subtype B and CRF01_AE. Conclusion Our cost-effective in-house genotypic resistance test detected no significant difference in drug resistance-related mutations frequencies between HIV-1 subtype B and CRF01_AE in Hong Kong. A drug resistance-related mutations database for different HIV-1 genotypes should be established in Hong Kong to augment guidance for HIV treatment.en_US
dc.languageengen_US
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_US
dc.relation.ispartofHong Kong Medical Journalen_US
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAntiretroviral therapy-
dc.subjectDrug resistance-
dc.subjectGenotype-
dc.subjectHighly active-
dc.subjectHIV-1-
dc.subjectMissense-
dc.subjectMutation-
dc.subjectViral-
dc.subject.meshAnti-Hiv Agents - Pharmacologyen_US
dc.subject.meshAntiretroviral Therapy, Highly Active - Methodsen_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshCost-Benefit Analysisen_US
dc.subject.meshDrug Resistance, Viral - Geneticsen_US
dc.subject.meshGenetic Techniques - Economicsen_US
dc.subject.meshGenotypeen_US
dc.subject.meshHiv Infections - Drug Therapy - Virologyen_US
dc.subject.meshHiv-1 - Genetics - Isolation & Purificationen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMutationen_US
dc.subject.meshRna, Viralen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.titleIn-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kongen_US
dc.typeArticleen_US
dc.identifier.emailYam, WC:wcyam@hkucc.hku.hken_US
dc.identifier.authorityYam, WC=rp00313en_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.pmid22302906-
dc.identifier.scopuseid_2-s2.0-84863142214en_US
dc.identifier.hkuros226014-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857164900&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume18en_US
dc.identifier.issue1en_US
dc.identifier.spage20en_US
dc.identifier.epage24en_US
dc.identifier.isiWOS:000301862400004-
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridChen, JHK=54999807800en_US
dc.identifier.scopusauthoridWong, KH=7404758411en_US
dc.identifier.scopusauthoridLi, PCK=36068280500en_US
dc.identifier.scopusauthoridChan, KKC=36915710700en_US
dc.identifier.scopusauthoridLee, MP=55000751300en_US
dc.identifier.scopusauthoridTo, SWC=36638680200en_US
dc.identifier.scopusauthoridYam, WC=7004281720en_US
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats